Skip to Main Content

It was not an executive shakeup that pummeled shares of Sarepta Therapeutics on Thursday. It was not rumors of a takeover Wall Street didn’t like.

Instead, it was a mistake.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!